Sector: MedicalPozen, Inc. (NASDAQ: POZN)
Ranking History
Scan Date: | 11/17/2009 |
Sector: | Medical |
Funamental : | 10 |
Technical : | 119 |
Performance : | 234 |
Overall: | 98 |
Number of Stocks: | 307 |
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 11 |
Technical : | 302 |
Performance : | 290 |
Overall: | 239 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 14 |
Technical : | 304 |
Performance : | 294 |
Overall: | 251 |
Number of Stocks: | 306 |
Headlines
- BioMed News Bytes: CombinatoRx, Dendreon, Photocure, Pozen
Nov 20, 2009 03:08 PM | CRL, CRXX, DNDN, POZN
- POZEN Announces Start of Enrollment For PA32540 Phase 3 Program
Nov 20, 2009 08:30 AM | POZN
- POZEN To Present at the Credit Suisse Healthcare Conference
Oct 30, 2009 07:30 AM | AZN, GSK, POZN
- Earnings News : WellPoint (WLP), Pozen (POZN), Boston Properties (BXP), FMC Technologies Inc. (FTI)
Oct 28, 2009 10:47 AM | BXP, FTI, POZN, WLP
- Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults
Oct 27, 2009 08:30 AM | POZN
- Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
Oct 19, 2009 09:01 AM | AZN, POZN
- POZEN Announces October 28, 2009 Webcast of Third Quarter 2009 Results
Oct 14, 2009 07:30 AM | GSK, POZN
- POZEN Inc. Announces Federal District Court Grants Motion to Dismiss Securities Class Action Lawsuit
Sep 30, 2009 04:00 PM | POZN
- POZEN To Present at the UBS Global Life Sciences Conference
Sep 09, 2009 08:01 AM | AZN, GSK, POZN, UBS
- POZEN Announces FDA Acceptance of NDA For VIMOVO(TM)
Aug 31, 2009 07:30 AM | POZN
- Pozen Beats Forecast, Foresees Good Fortune: Company Won't Need to Raise Operating Money in 2009
Feb 26, 2009 02:55 PM | AZN, GSK, POZN, RBC, TRI
- Drugmaker Pozen Extends Lease in Chapel Hill
Feb 20, 2009 01:20 PM | GBE, GSK, POZN
- '08 Contest Leaves Only 5 Entrants in the Black
Jan 11, 2009 03:23 PM | AKNS, AMD, AMGN, AMKR, DNDN, EBS
- '08 Blade Stock Contest Leaves Only 5 Entrants in the Black
Jan 11, 2009 02:20 PM | AKNS, AMD, AMGN, AMKR, DNDN, EBS
- Movers: Google, IBM, Schlumberger, Ambac, AIG, Honeywell
Oct 20, 2008 11:01 AM | ABK, AIG, AMD, BHP, CBI, COF
- POZEN Reports Third Quarter 2009 Results
Oct 28, 2009 07:52 AM | AZN, POZN
- POZEN Names Elizabeth A. Cermak As Executive Vice President, Chief Commercial Officer
Sep 14, 2009 07:51 AM | AZN, JNJ, POZN
- POZEN Reports Second Quarter 2009 Results
Jul 28, 2009 07:58 AM | AZN, POZN
- POZEN To Present at the 2009 BMO Capital Markets Focus on Healthcare Conference
Jul 22, 2009 08:03 AM | POZN
- POZEN Announces July 28, 2009 Webcast of Second Quarter 2009 Results
Jul 14, 2009 08:06 AM | POZN
- POZEN Submits New Drug Application For VIMOVO™ (PN 400)
Jun 30, 2009 08:34 AM | POZN
- POZEN Announces Election of Angela M. Larson to Board of Directors
Jun 09, 2009 08:15 AM | POZN
- POZEN Receives Decision From AstraZeneca to File PN 400 NDA
May 13, 2009 07:52 AM | AZN, POZN
- POZEN Reports First Quarter 2009 Results
Apr 30, 2009 08:00 AM | AZN, POZN
- POZEN Announces April 30, 2009 Webcast of First Quarter 2009 Results
Apr 16, 2009 08:16 AM | POZN
- Form 4 Cermak Elizabeth For: Sep 14 (10K)
Sep 15, 2009 05:43 PM
- Form 3 Cermak Elizabeth For: Sep 14 (10K)
Sep 15, 2009 05:42 PM
- Form 4 PLACHETKA JOHN R For: Aug 31 (10K)
Sep 02, 2009 05:44 PM
- Form 4 PLACHETKA JOHN R For: Aug 24 (10K)
Aug 26, 2009 05:38 PM
- Form 4 PLACHETKA JOHN R For: Aug 17 (10K)
Aug 19, 2009 05:41 PM
- Form 4 PLACHETKA JOHN R For: Aug 10 (10K)
Aug 12, 2009 05:42 PM
- Form 4 BARNHARDT JOHN E For: Jul 15 (10K)
Jul 17, 2009 05:40 PM
- Form 4 Kirsch Arthur S For: Jun 03 (10K)
Jun 05, 2009 05:34 PM
- Form 4 LEE KENNETH B JR For: Jun 03 (10K)
Jun 05, 2009 05:34 PM
- Form 4 MAUZEY JAMES JOSEPH For: Jun 03 (10K)
Jun 05, 2009 05:33 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
POZN
|
Compare to S&P
|
| YTD |
37.90 %
|
14.13 %
|
| 4 Weeks |
7.25 %
|
6.10 %
|
| 12 Weeks |
7.42 %
|
1.27 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 257.14 %
|
|
EPS Growth in Last Year: 184.62 %
|
|
Sales Growth in Last Quarter: 190.68 %
|
|
Sales Growth in Last Quarter: 28.22 %
|
|
